EA202091577A1 - Глюкуронилирование в качестве новой кислотной посттрансляционной модификации терапевтических моноклональных антител - Google Patents

Глюкуронилирование в качестве новой кислотной посттрансляционной модификации терапевтических моноклональных антител

Info

Publication number
EA202091577A1
EA202091577A1 EA202091577A EA202091577A EA202091577A1 EA 202091577 A1 EA202091577 A1 EA 202091577A1 EA 202091577 A EA202091577 A EA 202091577A EA 202091577 A EA202091577 A EA 202091577A EA 202091577 A1 EA202091577 A1 EA 202091577A1
Authority
EA
Eurasian Patent Office
Prior art keywords
glucuronylation
monoclonal antibodies
therapeutic monoclonal
translation modification
new acid
Prior art date
Application number
EA202091577A
Other languages
English (en)
Inventor
Шунхай Ванг
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of EA202091577A1 publication Critical patent/EA202091577A1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/2201—Streptopain (3.4.22.10)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/89—Inverse chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96402—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals
    • G01N2333/96405—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general
    • G01N2333/96408—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general with EC number
    • G01N2333/96413—Cysteine endopeptidases (3.4.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material

Abstract

Предусмотрены композиции и способы для выявления глюкуронилированных продуктов, представляющих собой белковое лекарственное средство.
EA202091577A 2018-01-31 2019-01-29 Глюкуронилирование в качестве новой кислотной посттрансляционной модификации терапевтических моноклональных антител EA202091577A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862624338P 2018-01-31 2018-01-31
PCT/US2019/015549 WO2019152356A2 (en) 2018-01-31 2019-01-29 Glucuronylation as a new acidic post-translational modification on therapeutic monoclonal antibodies

Publications (1)

Publication Number Publication Date
EA202091577A1 true EA202091577A1 (ru) 2020-10-26

Family

ID=65576657

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091577A EA202091577A1 (ru) 2018-01-31 2019-01-29 Глюкуронилирование в качестве новой кислотной посттрансляционной модификации терапевтических моноклональных антител

Country Status (16)

Country Link
US (2) US11366123B2 (ru)
EP (1) EP3746472A2 (ru)
JP (2) JP7301054B2 (ru)
KR (1) KR20200115467A (ru)
CN (1) CN112135839A (ru)
AR (1) AR114569A1 (ru)
AU (1) AU2019213647A1 (ru)
BR (1) BR112020011797A2 (ru)
CA (1) CA3084181A1 (ru)
EA (1) EA202091577A1 (ru)
IL (1) IL276075A (ru)
MX (1) MX2020008115A (ru)
SG (1) SG11202005015XA (ru)
TW (2) TWI808123B (ru)
WO (1) WO2019152356A2 (ru)
ZA (1) ZA202003320B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
AU2019213647A1 (en) 2018-01-31 2020-07-23 Regeneron Pharmaceuticals, Inc. Glucuronylation as acidic post-translational modification on therapeutic monoclonal antibodies
AU2021396379A1 (en) * 2020-12-11 2023-07-06 Genentech, Inc. Methods for determining the relative distribution of glucuronidation, iduronidation, and galacturonidation of polypeptides
US20230018713A1 (en) * 2021-07-13 2023-01-19 Regeneron Pharmaceuticals, Inc. Characterization of proteins by anion-exchange chromatography mass spectrometry (aex-ms)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110294150A1 (en) 2009-02-09 2011-12-01 Hans Koll Immunoglobulin glycosylation pattern analysis
IN2012DN03911A (ru) 2009-10-09 2015-09-04 Symphogen As
DK2732021T3 (da) 2011-07-08 2020-07-27 Emd Millipore Corp Forbedrede dybdefiltre til bioteknologiske engangsfremgangsmåder
WO2013190083A1 (en) 2012-06-21 2013-12-27 Philip Morris Products S.A. Systems and methods relating to network-based biomarker signatures
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
JP2019508380A (ja) * 2016-01-10 2019-03-28 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｅｇｆｒに対するグリコシル化キメラ抗体での癌の処置のための改善された安全性
AU2019213647A1 (en) 2018-01-31 2020-07-23 Regeneron Pharmaceuticals, Inc. Glucuronylation as acidic post-translational modification on therapeutic monoclonal antibodies

Also Published As

Publication number Publication date
MX2020008115A (es) 2020-09-25
BR112020011797A2 (pt) 2020-11-17
JP2021512280A (ja) 2021-05-13
US20190234964A1 (en) 2019-08-01
TW201940884A (zh) 2019-10-16
JP2023134463A (ja) 2023-09-27
WO2019152356A2 (en) 2019-08-08
TW202348623A (zh) 2023-12-16
US11366123B2 (en) 2022-06-21
AU2019213647A1 (en) 2020-07-23
CN112135839A (zh) 2020-12-25
US20220276260A1 (en) 2022-09-01
CA3084181A1 (en) 2019-08-08
IL276075A (en) 2020-08-31
TWI808123B (zh) 2023-07-11
AR114569A1 (es) 2020-09-23
JP7301054B2 (ja) 2023-06-30
EP3746472A2 (en) 2020-12-09
WO2019152356A3 (en) 2019-10-17
SG11202005015XA (en) 2020-06-29
KR20200115467A (ko) 2020-10-07
ZA202003320B (en) 2023-10-25

Similar Documents

Publication Publication Date Title
EA202091577A1 (ru) Глюкуронилирование в качестве новой кислотной посттрансляционной модификации терапевтических моноклональных антител
BR112018073761A2 (pt) proteínas de ligação ao cd3 de fragmento variável de cadeia única
EA202092410A1 (ru) Конъюгаты камптотецина с пептидом
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
EA202092907A1 (ru) Мультиспецифические связывающие белки и их усовершенствования
MD3313884T2 (ro) Anticorpi anti-CD123 şi conjugaţi şi derivaţi ai acestora
EA201891291A1 (ru) Мультиспецифические антитела
CO2020010345A2 (es) Dominios variables de anticuerpos que se dirigen al receptor nkg2d
EA201890530A1 (ru) Конъюгаты антитела к dll3 и лекарственного средства и способы их применения
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
UA117364C2 (uk) Похідні аматоксину
PH12019502576A1 (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
EA201891399A1 (ru) Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
EA201991704A2 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
BR112017006598A2 (pt) anticorpo de repetições antidipeptídeo derivado de ser humano (dprs)
EA202092202A1 (ru) Конструкции антител к ror
EA201791227A1 (ru) РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM
EA202191476A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA202190588A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
BR112018071107A2 (pt) composições e métodos para a detecção de proteínas da célula hospedeira
CY1123982T1 (el) Θεραπευτικη αγωγη για το πολλαπλο μυελωμα (μμ)
EA202090084A1 (ru) Новый терапевтический ферментный слитый белок и его применение
CO2021009129A2 (es) Tubulisinas y conjugados de proteína-tubulisina
CL2021002182A1 (es) Formulación de anticuerpos terapéuticos
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins